Hepatitis C virus-associated giomerulonephritis. Effect of a-interferon therapy. Hepatitis C virus (HCV) infection may present as a primary glomerular disease. We report 34 adult patients who presented with proteinuria and had circulating anti-HCV antibodies. Primary risk factors included a history of intravenous drug abuse (56%) or blood transfusion (18%). Patients presented with nephrotic syndrome (71%) or with nonnephrotic proteinuria (29%) and had membranoproliferative or acute proliferative glomerulonephritis on renal biopsy. Signs of clinical liver disease were infrequent (18%), though elevated liver function tests were common (66%) and liver biopsy in 16 of 18 patients showed chronic active hepatitis. Cryoglobulinemia was frequent (59%), but only 44% had extrarenal manifestations. In 100% of cases tested, HCV RNA could be found in the serum or cryoprecipitates. Fourteen patients received interferon alpha for 6 to 12 months with a significant reduction in proteinuria but no improvement in renal function. A good clinical response correlated with disappearance of HCV RNA from the serum during treatment; however, relapse of viremia and renal disease was common after completing therapy. Evidence for HCV infection should be sought in all patients with primary glomerular disease. The optimal treatment strategy, however, remains to be defined.
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It is now established that hepatitis C virus (HCV) infection is a major cause of mixed cryoglobulinemia [1] [2] [3] [4] [5] [6] . Less well known, however, is that HCV infection may cause membranoproliferative, proliferative, or membranous glomerulonephritis [7] [8] [9] [10] [11] [12] . Although ciyoglobulinemia is commonly present in patients with HCV-associated glomerulonephritis, many have no extrarenal manifestations of cryoglobulinemia and liver function tests may be normal [7] [8] [9] [10] [11] [12] . As such, the clinical presentation often suggests a primaly renal disease.
We report the clinical and virologic manifestations of 34 patients with HCV-associated glomerulonephritis, with special emphasis on their response to recombinant interferon alpha (IFN-a) therapy.
Methods
Consultation was provided on forty adult patients with proteinuria and a positive antibody test for HCV infection who underwent a renal biopsy by practicing nephrologists. All but one of Received for publication May 18, 1994 and in revised form July 14, 1994 Accepted for publication July 18, 1994 © 1994 by the International Society of Nephrology these patients were negative for the hepatitis B surface antigen (HBsAg). The patient who had circulating HBsAg at the time of presentation tested negative for both HBV DNA and HCV RNA by reverse transcriptase polymerase chain reaction (RT-PCR). This patient, who had MPGN type III, had a 50% reduction in proteinuria following his spontaneous loss of HBsAg and the appearance of anti-HBs antibodies in his serum, and was therefore considered to have a HBV associated MPGN and was excluded from the study. Five patients had membranous nephropathy on renal biopsy and will be the subject of a separate report. Of the remaining 34 patients, 20 were from the state of Washington, whereas the rest were referred from elsewhere in the United States. The initial presentation of five of these patients has been previously reported [7] .
Verification of HCV infection was obtained in all patients by testing for the presence of HCV antibodies using the second generation enzyme immunoassay (Abbott Laboratories, North Chicago, Illinois, USA) or by recombinant immunoblot assay (Ortho Diagnostics, Raritan, New Jersey, USA). In all cases in which serum and cryoprecipitates were available, the presence of HCV RNA was sought by RT-PCR using primers derived from the 5'-noncoding, highly conserved region of the HCV genome as previously described [7] . HCV genotyping was performed by PCR using primers specific for the HCV core region [13] and confirmed by sequence analysis of the NS5 region [14] .
After giving informed consent, 19 patients were treated with recombinant IFN-a (Intron-A, Schering-Plough, Bloomfield, New Jersey). Treatment was administered as 3 million U subcutaneously three times per week for 6 to 12 months, with dosage adjustments made depending on tolerance of the treatment.
Results
Thirty-four patients were identified with proteinuria and circulating anti-HCV antibodies. The mean age was 46 years (range 36 to 80); 59% were male; the majority (74%) were white, although some were black (9%), Hispanic (6%), Filipino (6%), and Asian (6%). Risk factors for HCV infection were present in 79% of patients; these included a history of intravenous drug abuse (56%) which was often remote, and prior blood transfusion (18%). Two patients (6%) gave a history of sexual exposure to HCV (both had partners that were intravenous drug addicts, and one of the addicts had a history of nonA-nonB hepatitis). No response
Patients presented with proteinuria and positive HCV antibody were categorized as to the presence of extrarenal signs of mixed cryoglobulinemia (EMC) or whether they appeared to have primary glomerular disease (GN), and whether or not cryoglobulinemia (Cryo) was detected. Four patients did have a history of a purpuric rash, but were initially negative for cryoglobulinemia at the time of renal biopsy (EMC, Cryo-). These latter patients, however, developed clyoglobulinemia over the ensuing months.
Abbreviations are: ALT, alanine aminotransferase; AST, aspartate aminotransferase; RF, rheumatoid factor. a 2 cases also showed a small to medium vessel arteritis b Signs of liver disease (ascites, hepatomegaly, or telangiectasia) C Treated for 6 months or longer Clinical presentation All patients were referred to nephrologists for the evaluation of proteinuria and microhematuria. However, the clinical presentation differed among the patients (Table 1 ). In 11 patients extrarenal signs of cryoglobulinemia (for example, purpura, arthralgias, cardiomyopathy, etc.) were present in association with circulating cryoglobulins, consistent with a diagnosis of "essential" mixed cryoglobulinemia (EMC). Nineteen patients appeared to have a primary glomerular disease; however, nine of these patients had circulating cryoglobulins. Four patients gave a history of a purpuric rash in addition to the renal disease suggestive of EMC, but initially tested negative for cryoglobulinemia.
Despite the differences in clinical presentation, virologic and laboratory analyses were remarkably similar between groups (Table 1 ). In addition, patients could switch categories over time. Five patients who initially presented with a noncryoglobulinemic glomerular disease subsequently developed detectable cryoglobulinemia, and in two of these cases this was associated with the development of purpura (Table 1 ). In addition, all four patients with a history of purpuric rash and noncryoglobulinemic MPGN eventually tested positive for cryoglobulinemia (Table 1) . Given these considerations, the clinical features of the group of patients as a whole will be considered in the subsequent sections. However, specific analysis of the clinical features of each group can be found in Table 1 .
Renal manifestations
Patients presented with nephrotic (that is, > 3.5 g'day; 71%) or non-nephrotic (29%) proteinuria (24 hr urine protein excretion of 5.9 5.2 g/day, range 0.5 to 28) with modest azotemia (serum creatinine 1.8 0.9 mg/dl, range 1.0 to 5.6). Hypoalbuminemia (3.0 g/dl or lower) was present in the majority (72%) of patients (mean concentration 2.8 0.5 g/dl). Renal biopsy demonstrated a membranoproliferative glomerulonephritis (MPGN) type I in 28 cases (82%). In three cases (9%) MPGN type III was diagnosed, as defined as an MPGN-type lesion in which immune deposits were found in subepithelial areas in addition to the subendothehum and mesangium. In three cases (9%) an acute proliferative and exudative nephritis was diagnosed, and in two cases an arteritis involving small and medium renal arterial vessels was also present. Immunofluorescence demonstrated capillary wall deposition of 1gM (88%), IgG (65%), and C3 (82%) in the majority of cases, but deposition was often scant. Electron microscopy in 29 cases revealed subendothelial dense deposits in 93% of cases, occasionally (14%) with coexistent subepithelial and intramembranous deposits.
Hepatic manifestations
Clinical signs of liver disease (that is, spider telangiectasias, hepatomegaly or ascites) were infrequent (18%); however, liver enzymes (alanine and/or aspartate aminotransferase levels) were mildly elevated in two-thirds of these patients. Despite the minimal evidence for liver disease, liver biopsy in 18 patients revealed chronic active hepatitis (N = 16), often with cirrhosis (N = 9); in two cases chronic persistent hepatitis was present.
Presence of cyog1obulinemia and other laboratory findings
Cryoglobulinemia was present in 59% of patients at presentation; however, an additional 26% developed cryoglobulinemia during the subsequent months. In seven cases the cryoglobulins were typed and shown to be type II, usually with an IgMK (N = 6); although an IgMA (N 1) was also observed. Despite the presence of cryoglobulinemia, extrarenal manifestations of cryoglobulinemia were absent in the majority (56%) of patients at presentation, although eventually 50% did have some extrarenal signs ( Table 1 ). The extrarenal manifestations consisted of purpura (35%), arthralgias (12%), neuropathy (9%), abdominal pain (6%), and cardiomyopathy (6%). One patient also had a non-Hodgkins lymphoma.
Other laboratory findings included depressed total plasma hemolytic complement (CH5O) (90% of cases tested), and low C3 (48%) and C4 (69%) levels. Rheumatoid factor activity was present in 72%, and antinuclear antibodies were either absent (88%) or present in low titer (12%). Anti-neutrophil cytoplasmic antibodies were negative in the 17 cases tested.
Virologic studies All 34 patients had evidence for HCV infection based on the presence of anti-HCV antibodies. Evidence for prior hepatitis B virus (HBV) infection was present in 14 of 31 cases tested (that is, anti-HB core Ag or anti-HBs antibodies). In addition, HCV RNA was detected (by PCR) in the serum of 28 of 28 cases tested (100%), and in the cryoglobulins of 22 of 23 cases (96%). In one patient HCV RNA was detected in only one of three blood samples. HCV genotyping was performed on the sera of 26 patients. Genotype analysis was performed on 29 isolates (due to 3 patients with dual infections), and were classified as type I (N = 9), type II (N = 11), type III (N = 2), and type IV (N = 7) (types la, ib, 2a, and 2b, respectively, according to Simmonds et al [14] ).
Effect of treatment with recombinant interferon alpha IFN-a has been administered to 19 patients; in two cases it was discontinued due to either worsening neuropathy or the development of erythema multiforme. In another case IFN-a was administered to a patient with a creatinine of 5.2 mg/dl and a urinary protein excretion of 28 glday. This patient's renal disease progressed rapidly and the a-IFN was discontinued at one month when dialysis became necessary.
Fourteen of the 16 remaining patients have received six or more months of IFN-a. In these patients, urine protein excretion was reduced (pretreatment 5.8 4.1 g/day vs. post-treatment 2.0 2.6 g/day, P < 0.005 by paired Student's t-test). In seven cases protein excretion decreased to less than 1 g/day, In 11 of 14 cases, serum creatinine improved 0.2 mg/dl or greater. However, no significant improvement in serum creatinine was observed when all of the patients were analyzed as a group (pretreatment 2.0 0.7 mg/dl vs. posttreatment 1.5 0.6 mg/dl, P = NS).
In 11 cases sera was tested for HCV RNA while on therapy. The six patients that became negative for HCV RNA during therapy had a relatively better clinical response to IFN-a than the five patients who remained HCV RNA positive ( The relationship between the clinical response to IFN-a and the HCV genotype was examined. A complete remission of the proteinuria (that is, <500 mg/day) was observed in four patients (1 type I and 3 type II); a partial remission (protein excretion <2 gms/d) was seen in six patients (1 type 1, 1 type II, 1 type IV, 1 with dual infection with types I and IV, and 2 that were not typed); and proteinuria greater than 2 g/day persisted in four (3 patients with type I, and 1 patient that was not typed). In addition, three of the five patients that remained HCV RNA positive during therapy had the type I HCV genotype.
Five of the six patients that became negative for HCV RNA in their serum have discontinued the IFN-a. In all cases, viremia has recurred within three months of completing therapy. This was followed by a rise in liver function tests (3 cases, at 4 to 5 months), a recurrence of the nephrotic syndrome (3 cases between 2 and 18 months), and recurrent purpura (1 case at 3 months). IFN-a therapy has been re-initiated in three of these patients. In three patients who have remained HCV RNA positive on standard doses of c-IFN, the dose has been increased to 5 to 6 million U three times weekly. Although the data are preliminary, one of these patients appears to be responding (serum creatinine has decreased from 3.4 mg/dl to 1.6 mg/dl with a decrease in protein excretion from 14 g/day to 2.3 g/day).
Side effects of IFN-a included a flu-like syndrome observed in the majority of patients and which gradually improved during therapy. Occasional patients complained of fatigue, irritability, depression, or headache. Two patients developed erythema multiforme. Three patients were also given erythropoietin (50 units per kg of body weight per week) because of anemia.
Immunosuppressive treatment has also been administered to patients with HCV-associated nephritis. No effect on renal function was observed in five patients treated with oral prednisone, although it may have improved the purpura seen in two patients.
One patient with EMC and MPGN was being tapered off of prednisone during a-IFN therapy and had a flare of his renal disease when his prednisone dose was reduced from 5 to 2.5 mg/day, with a sudden increase in his creatinine (from 1.3 to 2.8 mg/dl) and protein excretion. This patient, who had continued to be HCV RNA positive on a-IFN therapy, was then administered a short course of high dose oral steroids which was associated with an improvement in his creatinine to 1.7 mg/dl. Pulse steroids (1 g i.v. daily for 3 days followed by a tapering oral prednisone course) were given to two patients, including to one patient who had become dialysis dependent over several weeks prior to this therapy. One of these patients had EMC with cryoglobulinemic MPGN whereas the other patient had noncryoglobulinemic Table 2 . Clinical response of renal disease to IFN-a therapy as it relates to the suppression of viremia during therapy MPGN. In both cases an improvement in renal function was observed, and in the one patient dialysis has been discontinued and the creatinine is now 2.4 mg/dl. However, both patients remain HCV RNA positive. Cytotoxic agents and corticosteroids, with/without plasma exchange, have also been administered to five patients. Three of these patients (including two patients that were 77 and 80 years old) died of sepsis, pneumonia, and/or adult respiratoly distress syndrome. One patient who received chemotherapy for his lymphoma, and one patient who received a liver transplant, have had improvement in their renal function, but have had either an exacerbation or recurrence of their hepatitis and have remained HCV RNA positive.
Discussion
Our studies (7, and the current report) and that of others [5, [8] [9] [10] [11] [12] have demonstrated that HCV infection may be associated with renal disease. Whereas the association of HCV infection with "essential" mixed cryoglobulinemia is well-known [1] [2] [3] [4] [5] [6] , it is also apparent that HCV infection may manifest as a primary glomer- This also raises the question of whether or not idiopathic MPGN type I should be considered a distinct entity. Studies performed in the early 1970s demonstrated a significant occurrence of cryoglobulinemia in three "primary" glomerular diseases; specifically, MPGN, acute proliferative GN, and lupus nephritis [15] . Thirty-two percent of patients with MPGN were found to have cryoglobulinemia [15] . It seems likely that many of these patients had HCV infection.
In this study, patients were referred to nephrologists for evaluation of HCV infection and proteinuria. Most patients (71%) presented with nephrotic syndrome, and hypoalbuminemia was often severe. Clinical evidence of liver disease (that is, ascites or hepatomegaly) was observed in only 18% of patients, although mildly elevated liver enzymes were frequently present, and when liver tissue was examined chronic active hepatitis was diagnosed in 89% of cases. In the great majority of sera and cryoprecipitates tested, HCV RNA was isolated. Genotyping showed that the majority of cases were HCV type I or type II, which are the more common genotypes present in United States (J. Lau, personal communication).
Fourteen patients were treated with IFN-a for at least six months. A significant reduction in proteinuria was observed, whereas renal function improved but the improvement did not reach statistical significance. Interestingly, not all patients treated with IFN-a had a beneficial response, and this correlated with whether or not HCV RNA remained detectable in the serum or cryoprecipitates. Indeed, the three patients who did not appear to respond at all to IFN-a remained HCV RNA positive and carried the type I genotype. This genotype has been reported to be relatively more resistant to IFN-a therapy [16] .
Recently, Misiani et al reported a controlled study examining the effect of IFN-a on the mixed cryoglobulinemia associated with HCV [17] . These authors noted a significant reduction in purpura and circulating cryoglobulins in those patients who became HCV RNA negative during therapy [17] . One significant difference between their study and ours was that patients were entered into their series if they had symptoms of EMC (that is, fatigue, arthralgias and purpura) and evidence for HCV infection, whereas our patients were referred to nephrologists for evaluation of glomerular disease. Although renal involvement, as manifested by proteinuria and hematuria, was observed in two-thirds of their patients, the renal disease was mild, as the mean creatinine was 1.2 mg/dl, the protein-creatinine ratio was 0.24 (equivalent to less than 1 gram per day), and no renal biopsy findings were provided. In contrast, 71% of our patients had nephrotic range proteinuria, 72% had serum albumin levels less than or equal to 3 g/dl, 68% had a creatinine of 1.4 mg/dl or greater (with 2 eventually requiring dialysis), and all underwent renal biopsy. Although the pathogenic processes are likely similar in these studies, the current series does provide the first detailed information on the spectrum of HCV associated glomerular disease and its responsiveness to IFN-a. In that regard, proteinuria was significantly reduced with therapy, and, like the Misiani study [17] , the beneficial effects of IFN-a were most impressive in those patients in which the HCV RNA was suppressed during therapy. Unfortunately, relapse of viremia and renal disease were common after therapy was discontinued. The optimal treatment strategy for patients with HCV-associated GN has yet to be established. It is possible that higher doses or longer duration of therapy with IFN-a may be required. It is also possible that combination therapies using interferon-a with other antiviral drugs such as ribavirin may be more effective [18] .
An alternative to IFN-a is immunosuppressive therapy, which may work in these patients by suppressing the antibody response as opposed to eliminating the antigen (that is, virus). In our limited number of patients oral prednisone was without clinically apparent effect on the renal disease, whereas cytotoxic therapy appeared to be associated with severe untoward side effects. Pulse steroid therapy was associated with improvement in the renal function in the two patients who received this therapy, and is consistent with studies by others using pulse steroid therapy in cryoglobulinemic GN [19] . However, one problem with immunosuppressive therapies is that circulating HCV RNA levels increase [20] , and the consequence of the increased HCV viremia on the underlying liver disease remains to be determined. Ultimately, controlled trials comparing these types of therapy are indicated. physicians who have provided primary care to these patients and permitting us to study and report on them.
